Synchron Raises US$200 Million in Series D Funding to Advance BCI Technology
Synchron has secured US$200 million in a Series D funding round to boost the commercialisation of its first-generation Stentrode brain-computer interface (BCI) platform. The company also aims to accelerate the development of its next-generation transcatheter, high-channel whole-brain interface.
The investment will support pivotal clinical trials and preparations for the official commercial launch of the Stentrode BCI system. Synchron noted that, strengthened by this funding, it plans to expand its team by hiring additional engineers, neuroscientists, and operators to further advance brain-computer interface technologies.
Investors and Strategy
- Lead investor: Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
“Bolstered by this Series D funding, Synchron will continue hiring top talent and advancing the next generation of BCIs,” the company stated in its release.
This latest financing round raises Synchron’s total funding to US$345 million, according to the company’s announcement.
Author’s Summary
Synchron’s US$200 million Series D boost underscores its rapid growth and determination to bring minimally invasive brain-computer interfaces closer to commercial reality.